Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemoradiotherapy versus chemoradiotherapy alone in high-risk locoregionally advanced nasopharyngeal carcinoma
ChiCTR2500102269Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of QL1706 in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Failure-free survival and Overall survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500102269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102269.